Since 2009 the MALDI-TOF MS based identification of bacteria increased with the number of reference spectra in the libraries. To date, our findings constitute a proof of concept that moulds identification can be adapted to the routine clinical laboratory and it is likely that MALDI-TOF MS based identification moulds will also benefit from strengthening reference libraries. This novel standardized MALDI-TOF MS-based mould identification assay allowing the timely and accurate identification of clinically relevant moulds at the species level in the routine microbiology laboratory setting is likely to dramatically alter the management of fungal infections. Our findings demonstrate that MALDI-TOF MS identification is efficient for the rapid and routine identification of mould isolates in the clinical laboratory and, in line with the current practices of bacteria identification in the growing number of microbiology laboratories equipped with bench-top MALDI-TOF instruments, it could be used, ahead of morphological identification, as a first-line method for mould identification. Additionally, this MALDI-TOF MS identification process will have a great impact on several other research areas that would benefit from a high throughput and accurate mould identification assay. Indeed, moulds are of growing interest in human health, food safety management, and the control of phytopathogenic fungi. Some species have been associated with allergic diseases. In contrast, Ege et al. recently pointed to the significant protection against childhood asthma associated with exposure to farm microbiota, and especially fungal taxa. Furthermore, the human-health consequences of mycotoxins PLX4032 produced by species of Aspergillus, Penicillium, Claviceps, Fusarium, and Alternaria are of concern, as is the burden of phytopathogenic fungi on farming. With its potential to identify a wide array of microorganism species at the strain level within minutes, this unique microorganism identification approach will indubitably increase our understanding of the complex human health and environmental microbiota interactions in the very near future. MALDI-TOF MS recently became one of the routine microorganism identification tools in the clinical laboratory. This work’s seminal finding is that, akin to bacteria and yeasts, a standardized procedure can also be used for MALDI-TOF MSbased identification of a wide array of clinically relevant mould species. Usable in the routine clinical laboratory setting, it opens new avenues for the development of an integrated MALDI-TOF MS-based solution for the identification of any clinically relevant microorganisms. In man, the level of serum uric acid is determined primarily by the production of urate, as an end product of purine metabolism versus biliary and urinary tract elimination. In the majority of other mammals, uric acid is metabolized by uricase to allantoin, before urinary excretion. Thus man, has comparably higher serum uric acid levels than most mammals. The renal handling of uric acid is a complex and incompletely understood process. Uric acid is freely filtered at the glomerulus, the majority undergoes reabsorption via proximal tubular urate transporter proteins and a proportion is secreted back into the filtrate in the late proximal tubule.